Leo Pharma, Glenmark Settle Enstilar Psoriasis Drug Patent Suit

Leo Pharma A/S and Glenmark Pharmaceuticals Ltd. settled a patent-infringement lawsuit over Glenmark’s proposed generic version of Enstilar, a foam treatment for plaque psoriasis, according to Delaware federal court filings.

“Unless otherwise specifically authorized” in the confidential settlement agreement, Glenmark is blocked from making Enstilar copies until the patents have expired, according to a consent judgment and order of dismissal approved Monday in the U.S. District Court for the District of Delaware.

Leo sued Glenmark in October 2020, alleging that its proposed copycat infringes five patents for Enstilar that were issued earlier that year. All five patents expire in ...